文献速递糖尿病

多扎格列汀单药治疗中国2型糖尿病患者的剂量范围随机双盲安慰剂对照2期研究

Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2018-05-04

这项多中心随机双盲安慰剂对照2期研究将258例中国2型糖尿病患者随机分配至安慰剂或四种剂量多扎格列汀组,治疗12周。结果显示50 mg每日两次和75 mg每日两次组的HbA1c较基线变化与安慰剂组相比有显著差异,不良事件数与安慰剂组相似,无药物相关严重不良事件或严重低血糖报告。

要点

  • 多扎格列汀75 mg每日两次组HbA1c较基线变化为-1.12%,50 mg每日两次组为-0.79%,均显著优于安慰剂。
  • 100 mg每日一次和75 mg每日一次组HbA1c变化与安慰剂组相比未报告显著差异。
  • 不良事件数与安慰剂组相似,无药物相关严重不良事件或严重低血糖报告。

核心结论

  • 多扎格列汀在中国2型糖尿病患者中12周内对血糖控制有有益作用,且安全且耐受性良好。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照2期研究,随机分配258例患者至安慰剂或四种剂量多扎格列汀组(1:1:1:1:1)。
  • 纳入40-75岁、BMI 19.0-30.0 kg/m2、饮食运动控制、既往未治疗或二甲双胍或α-葡萄糖苷酶抑制剂单药治疗的中国2型糖尿病患者。
  • 研究包括4周安慰剂导入期和12周治疗期,主要终点为基线至第12周HbA1c变化。

主要发现

  • 第12周时HbA1c较基线最小二乘均值变化:安慰剂组-0.35%(95%CI -0.60至-0.10),75 mg每日一次组-0.39%(-0.64至-0.14),100 mg每日一次组-0.65%(-0.92至-0.38),50 mg每日两次组-0.79%(-1.06至-0.52),75 mg每日两次组-1.12%(-1.39至-0.86)。
  • 与安慰剂组相比,50 mg每日两次组(p=0.0104)和75 mg每日两次组(p<0.0001)的HbA1c变化有显著差异。
  • 不良事件数在治疗组与安慰剂组之间相似,无药物相关严重不良事件或严重低血糖报告。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glucokinase acts as a glucose sensor in the pancreas and a glucose processor in the liver, and has a central role in glucose homoeostasis. Dorzagliatin is a new, dual-acting, allosteric glucokinase activator that targets both pancreatic and hepatic glucokinases. Dorzagliatin has good pharmacokinetic and pharmacodynamic properties in humans, and provides effective 24-h glycaemic control and improves glucose sensitivity in patients with type 2 diabetes. We aimed to assess the efficacy and safety of dorzagliatin monotherapy at different doses in Chinese patients with type 2 diabetes. METHODS: In this multicentre, randomised, double-blind, placebo-controlled, phase 2 study, we randomly assigned (1:1:1:1:1) patients to receive oral placebo or one of four doses of oral dorzagliatin (75 mg once a day, 100 mg once a day, 50 mg twice a day, or 75 mg twice a day) using permuted-block randomisation, with a block size of ten and without stratification. Eligible patients were men or non-fertile women (aged 40-75 years) with type 2 diabetes who had a BMI of 19·0-30·0 kg/m2, were on a diet and exercise regimen, and were previously untreated or treated with metformin or α-glucosidase inhibitor monotherapy. The study started with a 4-week placebo run-in period followed by a 12-week treatment period. The primary endpoint was the change in HbA1c from baseline to week 12, which was assessed in all patients who received at least one dose of study drug and had both baseline and at least one post-baseline HbA1c value. Safety was assessed in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT02561338. FINDINGS: Between Sept 29, 2015, and Aug 17, 2016, we randomly assigned 258 patients to one of the five study groups. At the end of 12 weeks, the least squares mean change in HbA1c from baseline was -0·35% (95% CI -0·60 to -0·10) in the placebo group, -0·39% (-0·64 to -0·14) in the 75 mg once daily group, -0·65% (-0·92 to -0·38) in the 100 mg once daily group, -0·79% (-1·06 to -0·52) in the 50 mg twice daily group, and -1·12% (-1·39 to -0·86) in the 75 mg twice daily group. Compared with the placebo group, the change in HbA1c between baseline and 12 weeks was significant in the 50 mg twice daily (p=0·0104) and the 75 mg twice daily (p<0·0001) groups. The number of adverse events was similar between the treatment groups and the placebo group. There were no reports of drug-related serious adverse events or severe hypoglycaemia. INTERPRETATION: Dorzagliatin had a beneficial effect on glycaemic control and was safe and well tolerated over 12 weeks in Chinese patients with type 2 diabetes. FUNDING: Hua Medicine, National Major Scientific and Technological Special Project for Significant New Drugs Development, Shanghai Science and Technology Innovation Action Project, Shanghai Pudong District Science and Technology Innovation Action Project, and Shanghai Municipal Commission of Economy and Informatisation Innovation Action Project.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Zhu D, Gan S, Liu Y, et al. Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Diabetes Endocrinol. 2018. PMID: 29735394. doi:10.1016/S2213-8587(18)30105-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。